Sanofi (SNY)
| Market Cap | 119.04B |
| Revenue (ttm) | 53.89B |
| Net Income (ttm) | 10.69B |
| Shares Out | 1.22B |
| EPS (ttm) | 8.67 |
| PE Ratio | 11.13 |
| Forward PE | 10.56 |
| Dividend | $1.60 (3.26%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 1,960,178 |
| Open | 48.63 |
| Previous Close | 49.11 |
| Day's Range | 48.54 - 49.32 |
| 52-Week Range | 44.62 - 60.12 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 61.50 (+25.51%) |
| Earnings Date | Oct 24, 2025 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $61.5, which is an increase of 25.51% from the latest price.
News
UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care Expanded 10-plus-year collaboration will levera...
Sanofi: Is Dupixent Too Successful?
Sanofi delivered strong Q3 results despite currency headwinds. The company's dependence on Dupixent is increasing. A broad immunology pipeline and the Blueprint Medicines acquisition should help addre...
Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal
Sanofi (SNY) remains a Buy, driven by Dupixent's robust growth and expanding indications, notably with the recent COPD launch. SNY's Q3 saw total revenues rise 7% CER to €12.43 billion, with Dupixent ...
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark
Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.
Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance
Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.
Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged
France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its anti-inflammatory drug Dupixent and newer medicines.
Press release: Q3: continued sales and earnings progress
Q3: continued sales and earnings progress Paris, October 24, 2025 Q3 sales growth of 7.0% at CER1 and business earnings per share (EPS)2 of €2.91 Pharma launches increased sales by 57.1%, reaching €1....
Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
Expanded 10-plus-year collaboration will leverage Medidata Experiences, enabling Sanofi to streamline operations, refine data quality, and enhance patient care Expanded 10-plus-year collaboration will...
Press Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Press Release: Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically mean...
Press Release: Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant...
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency's Committee for Medicinal Products for ...
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced a ...
ITM Appoints Annette Breunig as Chief People Officer
Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief Peop...
BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform
TORONTO--(BUSINESS WIRE)--BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform.
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
AlphaMedix TM ( 212 Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)
Sanofi is repositioned as a pure pharma play. Following an earnings reset, we see support in ongoing buybacks and higher sales guidance. Q2 results showed strong Dupixent growth, and 2026 readouts off...
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s...
QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials
TEL AVIV, Isreal & CAMBRIDGE, Mass.--(BUSINESS WIRE)--QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of g...
A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff
Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...
Sanofi Expands Insulin Savings Program To Cover All US Patients
The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA's (NASDAQ: S...
Sanofi to offer all insulin products for $35 per month in US
French drugmaker Sanofi said on Friday it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status.